Analyst Oliver McCammon of LifeSci Capital maintained a Buy rating on Aura Biosciences Inc, with a price target of $23.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Oliver McCammon has given his Buy rating due to a combination of factors that highlight the potential of Aura Biosciences Inc. The company’s promising pipeline, particularly their bel-sar therapy, is a significant factor. This therapy, designed to target cancer cells with a dual mechanism, shows potential in treating ocular oncology and bladder cancer. The upcoming Phase 3 trial results for choroidal melanoma, expected by Q4 2027, are anticipated to be positive, given the progress in patient enrollment and identification.
Additionally, Aura’s expansion into other ocular oncology indications suggests a strategic move to establish a strong franchise in this field. With an estimated 60,000 annual cases in the US and Europe, the company is positioned to address a substantial market need. The ongoing development and expected data from these additional indications in 2026 further reinforce the company’s growth potential, justifying the Buy rating.
In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $22.00 price target.
Based on the recent corporate insider activity of 28 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of AURA in relation to earlier this year.